Advisors Management Group Inc. ADV Has $3.70 Million Stock Holdings in Pfizer Inc. $PFE

Advisors Management Group Inc. ADV lessened its holdings in Pfizer Inc. (NYSE:PFE) by 21.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,395 shares of the biopharmaceutical company’s stock after selling 39,525 shares during the quarter. Advisors Management Group Inc. ADV’s holdings in Pfizer were worth $3,695,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Peak Asset Management LLC increased its stake in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares during the period. Quest Investment Management LLC increased its position in shares of Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 405 shares during the period. Community Bank & Trust Waco Texas increased its holdings in Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after buying an additional 412 shares during the period. CVA Family Office LLC raised its position in shares of Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 413 shares in the last quarter. Finally, Boltwood Capital Management lifted its holdings in shares of Pfizer by 0.7% during the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 420 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 2.0%

Shares of Pfizer stock opened at $27.03 on Friday. The stock’s 50-day moving average is $26.84 and its 200 day moving average is $25.69. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The firm has a market cap of $153.70 billion, a price-to-earnings ratio of 19.88 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Bank of America dropped their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.